Anthropic Starts Its Own Drug Discovery Work, Acquires One-Person Biotech to Advance Pediatric Rare Disease Therapy Research

Anthropic buys a one-person biotech firm

On October 27, 2026 (US time), Anthropic said it is now doing drug discovery on its own. It bought Mithril Medicine, a US biotech company run alone by its founder, Cody Trunnberger. The company had been working on treatments for rare muscle diseases in children. Anthropic says the research now continues inside the company.

Key facts

• Mithril Medicine was run by one person, its founder Cody Trunnberger, who used Claude to handle contracts, logistics and lab planning with 11 outside research groups.
• Going from an idea to promising results in mice took under 18 months for one of two muscle diseases.
• In a small test in mice, one of two trial antibodies, given for 6 weeks, roughly doubled front-leg strength and grip strength compared with mice given a salt-water control.
• Claude sorted 113 candidate antibodies into three groups in under 8 minutes, after reading 341 pages of manufacturing data.
• At least 3 errors made by Claude got past human checks and reached outside testing labs.

The disease and the approach

The main target is LAMA2-related congenital muscular dystrophy. In this illness, a protein that holds muscle fibers to the membrane around them is missing. There is no cure yet. The team is building a drug with a bispecific antibody, which binds two targets at once. It links the muscle fibers to another protein still present in the muscle, so the membrane is held in place again. The company says the same idea might also work for alpha-dystroglycanopathy, the second target.

Why this matters

This shows AI doing many steps of a drug project that used to need a big team. It also shows the risk: AI can make mistakes that human checks miss, especially small details like numbers. Anthropic says it wants to work on diseases that big drug companies have not been interested in. If the drug stays promising, human trials could start as early as late 2028.

What to watch

• Whether the drug candidate stays promising in further tests.
• Whether human clinical trials start, possibly in late 2028.
• Anthropic's plan to start several new drug programs.
• How Anthropic works with its six other drug-development partners.